Advertisement

A rare frameshift variant in trans with the IVS9-5T allele of CFTR in a Chinese pedigree with congenital aplasia of vas deferens

  • Bin Ge
  • Mingzhe Zhang
  • Ruyi Wang
  • Dejing Wang
  • Tengyan Li
  • Hongjun LiEmail author
  • Binbin WangEmail author
Genetics
  • 42 Downloads

Abstract

Purpose

Congenital aplasia of vas deferens (CAVD) is an atypical form of cystic fibrosis (CF) and causes obstructive azoospermia and male infertility. Compound heterozygous variants of CFTR are the main cause of CAVD. However, most evidence comes from genetic screening of sporadic cases and little is from pedigree analysis. In this study, we performed analysis in a Chinese pedigree with two CAVD patients in order to determine the genetic cause of this familial disorder.

Methods

In the present study, we performed whole-exome sequencing and co-segregation analysis in a Chinese pedigree involving two patients diagnosed with CAVD.

Results

We identified a rare frameshift variant (NM_000492.3: c.50dupT;p.S18Qfs*27) and a frequent CBAVD-causing variant (IVS9-TG13-5T) in both patients. The frameshift variant introduced a premature termination codon and was not found in any public databases or reported in the literature. Co-segregation analysis confirmed these two variants were in compound heterozygous state. The other male members, who harbored the frameshift variant and benign IVS9-7T allele, did not have any typical clinical manifestations of CF or CAVD.

Conclusion

Our findings may broaden the mutation spectrum of CFTR in CAVD patients and provide more familial evidence that the combination of a mild variant and a severe variant in trans of CFTR can cause vas deferens malformation.

Keywords

CFTR CBAVD Compound heterozygous Chinese pedigree 

Notes

Funding information

This work was supported by funds from the National Natural Science Foundation of China (grant numbers 81671448 and 81871152).

Compliance with ethical standards

Written informed consent was obtained from all participants. This research was approved by the Research Ethics Committee of the Affiliated Hospital of Zunyi Medical University.

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995;332(22):1475–80.  https://doi.org/10.1056/NEJM199506013322204.CrossRefPubMedGoogle Scholar
  2. 2.
    Weiske WH, Salzler N, Schroeder-Printzen I, Weidner W. Clinical findings in congenital absence of the vasa deferentia. Andrologia. 2000;32(1):13–8.CrossRefGoogle Scholar
  3. 3.
    Yu J, Chen Z, Ni Y, Li Z. CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis. Hum Reprod. 2012;27(1):25–35.  https://doi.org/10.1093/humrep/der377.CrossRefPubMedGoogle Scholar
  4. 4.
    Wosnitzer MS, Goldstein M. Obstructive azoospermia. Urol Clin N Am. 2014;41(1):83–95.  https://doi.org/10.1016/j.ucl.2013.08.013.CrossRefGoogle Scholar
  5. 5.
    O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891–904.  https://doi.org/10.1016/S0140-6736(09)60327-5.CrossRefPubMedGoogle Scholar
  6. 6.
    Nistal M, Riestra ML, Galmes-Belmonte I, Paniagua R. Testicular biopsy in patients with obstructive azoospermia. Am J Surg Pathol. 1999;23(12):1546–54.CrossRefGoogle Scholar
  7. 7.
    Patat O, Pagin A, Siegfried A, Mitchell V, Chassaing N, Faguer S, et al. Truncating mutations in the adhesion g protein-coupled receptor G2 gene ADGRG2 cause an X-linked congenital bilateral absence of vas deferens. Am J Hum Genet. 2016;99(2):437–42.  https://doi.org/10.1016/j.ajhg.2016.06.012.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Yang B, Wang J, Zhang W, Pan H, Li T, Liu B, et al. Pathogenic role of ADGRG2 in CBAVD patients replicated in Chinese population. Andrology. 2017;5(5):954–7.  https://doi.org/10.1111/andr.12407.CrossRefPubMedGoogle Scholar
  9. 9.
    Khan MJ, Pollock N, Jiang H, Castro C, Nazli R, Ahmed J, et al. X-linked ADGRG2 mutation and obstructive azoospermia in a large Pakistani family. Sci Rep. 2018;8(1):16280.  https://doi.org/10.1038/s41598-018-34262-5.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yuan P, Liang ZK, Liang H, Zheng LY, Li D, Li J, et al. Expanding the phenotypic and genetic spectrum of Chinese patients with congenital absence of vas deferens bearing CFTR and ADGRG2 alleles. Andrology. 2019;7(3):329–40.  https://doi.org/10.1111/andr.12592.CrossRefPubMedGoogle Scholar
  11. 11.
    Davies B, Baumann C, Kirchhoff C, Ivell R, Nubbemeyer R, Habenicht UF, et al. Targeted deletion of the epididymal receptor HE6 results in fluid dysregulation and male infertility. Mol Cell Biol. 2004;24(19):8642–8.  https://doi.org/10.1128/MCB.24.19.8642-8648.2004.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sobel RE, Bate A, Marshall J, Haynes K, Selvam N, Nair V, et al. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System’s analytic tools. Pharmacoepidemiol Drug Saf. 2018;27(3):332–9.  https://doi.org/10.1002/pds.4392.CrossRefPubMedGoogle Scholar
  13. 13.
    Cai H, Qing X, Niringiyumukiza JD, Zhan X, Mo D, Zhou Y, et al. CFTR variants and renal abnormalities in males with congenital unilateral absence of the vas deferens (CUAVD): a systematic review and meta-analysis of observational studies. Genet Med. 2019;21(4):826–36.  https://doi.org/10.1038/s41436-018-0262-7.CrossRefPubMedGoogle Scholar
  14. 14.
    de Souza DAS, Faucz FR, Pereira-Ferrari L, Sotomaior VS, Raskin S. Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling. Andrology. 2018;6(1):127–35.  https://doi.org/10.1111/andr.12450.CrossRefPubMedGoogle Scholar
  15. 15.
    Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest. 1998;101(2):487–96.  https://doi.org/10.1172/JCI639.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Noone PG, Knowles MR. ‘CFTR-opathies’: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res. 2001;2(6):328–32.CrossRefGoogle Scholar
  17. 17.
    Feng JR, Zhang YN, Wu X, Yang XJ, Chen ST, Ma GC, et al. Homozygous 5T alleles, clinical presentation and genetic analysis within a family with congenital bilateral absence of the vas deferens. Zhonghua Yi Xue Za Zhi. 2018;98(18):1414–8.  https://doi.org/10.3760/cma.j.issn.0376-2491.2018.18.009.CrossRefPubMedGoogle Scholar
  18. 18.
    Yang B, Wang X, Zhang W, Li H, Wang B. Compound heterozygous mutations in CFTR causing CBAVD in Chinese pedigrees. Mol Genet Genomic Med. 2018;6(6):1097–103.  https://doi.org/10.1002/mgg3.486.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Mak V, Jarvi KA, Zielenski J, Durie P, Tsui LC. Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens. Hum Mol Genet. 1997;6(12):2099–107.CrossRefGoogle Scholar
  20. 20.
    Cuppens H, Cassiman JJ. CFTR mutations and polymorphisms in male infertility. Int J Androl. 2004;27(5):251–6.  https://doi.org/10.1111/j.1365-2605.2004.00485.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Radpour R, Gourabi H, Gilani MA, Dizaj AV. Molecular study of (TG)m(T)n polymorphisms in Iranian males with congenital bilateral absence of the vas deferens. J Androl. 2007;28(4):541–7.  https://doi.org/10.2164/jandrol.106.002337.CrossRefPubMedGoogle Scholar
  22. 22.
    Chu CS, Trapnell BC, Curristin SM, Cutting GR, Crystal RG. Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis. J Clin Invest. 1992;90(3):785–90.  https://doi.org/10.1172/JCI115952.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, Des Georges M, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet. 2004;74(1):176–9.  https://doi.org/10.1086/381001.CrossRefPubMedGoogle Scholar
  24. 24.
    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.  https://doi.org/10.1038/gim.2015.30.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lissens W, Mercier B, Tournaye H, Bonduelle M, Ferec C, Seneca S, et al. Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities. Hum Reprod. 1996;11(Suppl 4):55–78 discussion 79-80.CrossRefGoogle Scholar
  26. 26.
    Casals T, Bassas L, Egozcue S, Ramos MD, Gimenez J, Segura A, et al. Heterogeneity for mutations in the CFTR gene and clinical correlations in patients with congenital absence of the vas deferens. Hum Reprod. 2000;15(7):1476–83.  https://doi.org/10.1093/humrep/15.7.1476.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Reproductive Medicine Centerthe Affiliated Hospital of Zunyi Medical UniversityZunyiPeople’s Republic of China
  2. 2.Center for GeneticsNational Research Institute for Family PlanningBeijingPeople’s Republic of China
  3. 3.Department of Urology, Peking Union Medical College Hospital, Peking Union Medical CollegeChinese Academy of Medical SciencesBeijingPeople’s Republic of China

Personalised recommendations